香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負 責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或 任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Sinopharm Tech Holdings Limited 國藥科技股份有限公司 ( 於開曼群島註冊成立之有限公司 ) (股份代號: 8156) 董事會會議日期 國藥科技股份有限公司（「本公司」）董事會（「董事會」）宣佈本公司將於二 零二五年九月二十六日（星期五）舉行董事會會議，藉以（其中包括）考慮及批 准本公司及其附屬公司截至二零二五年六月三十日止年度之全年業績及其刊發， 考慮延遲支付本公司可換股優先股的年度優先分派，以及考慮派發本公司普通股 的末期股息（如有）。 承董事會命 Sinopharm Tech Holdings Limited 國藥科技股份有限公司 執行董事 趙善能 香港，二零二五年九月十六日 本公告的資料乃遵照香港聯合交易所有限公司 GEM 證券上市規則而刊載，旨在提 供有關本公司的資料，本公司的董事願就本公告資料共同及個別承擔全部責任。 各董事在作出一切合理查詢後，確認就其所知及所信 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 國藥科技股份有限公司 呈交日期: 2025年9月4日 第 1 頁 共 11 頁 v 1.1.1 FF301 備註： FF301 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08156 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 12,800,000,000 | HKD | | 0.0125 | HKD | | 160,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 12,800,000,000 | HKD ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 國藥科技股份有限公司 呈交日期: 2025年8月6日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08156 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 12,800,000,000 | HKD | | 0.0125 | HKD | | 160,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 12,800,000,000 | HKD | | 0.0125 | HKD | | 160,000,000 | | ...

Group 1 - The article provides a list of companies listed on the Hong Kong stock market along with their dividend distribution dates and shareholder meeting dates [1][4][5] - Notable companies mentioned include China Railway, Green Town China, and Budweiser APAC, which are scheduled for dividend payments [4][5] - The document outlines various companies' actions regarding capital increases and dividend distributions, indicating ongoing corporate activities in the market [4][5]

智通财经APP获悉，截止7月24日收盘，有190只股票创52周新高，其中大唐西市(00620)、国药科技股份 (08156)、环联连讯(01473)创高率位于前3位，分别为41.43%、37.50%、23.64%。 | 康臣药业(01681) | 12.860 | 12.860 | 2.06% | | --- | --- | --- | --- | | 药明合联(02268) | 57.100 | 57.700 | 2.03% | | 品质国际(00243) | 0.465 | 0.510 | 2.00% | | 浙江沪杭甬(00576) | 7.650 | 7.680 | 1.99% | | ＧＸ中美科技(03402) | 72.700 | 73.100 | 1.95% | | 隽思集团(01412) | 1.550 | 1.580 | 1.94% | | 新华保险(01336) | 48.300 | 48.700 | 1.88% | | 华夏日股对冲(03160) | 23.000 | 23.080 | 1.85% | | 基石药业－Ｂ(02616) | 7.580 | 7.700 | 1.85% | | ...

Core Viewpoint - As of July 18, 160 stocks reached their 52-week highs, with notable performances from China New Economy Investment (00080), Aoyuan Group Equity (02905), and Zhong An Holdings Group (08462) showing high growth rates of 288.89%, 55.28%, and 50.00% respectively [1][2]. Summary by Category 52-Week High Performers - China New Economy Investment (00080) closed at 0.440, with a peak price of 0.700, achieving a growth rate of 288.89% [2]. - Aoyuan Group Equity (02905) closed at 0.218, with a peak price of 0.250, achieving a growth rate of 55.28% [2]. - Zhong An Holdings Group (08462) closed at 0.221, with a peak price of 0.228, achieving a growth rate of 50.00% [2]. - Other notable performers include Hualian International (00969) with a growth rate of 40.13% and Zhongke Bio (01237) with a growth rate of 37.25% [2]. Additional High Performers - Wanma Holdings (06928) closed at 0.550 with a growth rate of 30.43% [2]. - Lepu Biopharma-B (02157) closed at 7.940 with a growth rate of 24.54% [2]. - Other stocks with significant growth include ZhiJianYueDong (06860) at 17.14% and China Jindian Group (08281) at 17.12% [2]. 52-Week Low Performers - The document also lists stocks that reached their 52-week lows, with XI Ernan CO-U (09311) showing a decline of 16.10% [6]. - Other notable declines include XI Ernan CO (07311) at -12.62% and Haotian International Construction Investment (01341) at -5.70% [6].

Group 1 - As of June 3, a total of 105 stocks reached their 52-week highs, with Huayin International Holdings (00989), Dingyifeng Holdings (00612), and Youquhui Holdings (02177) leading the high rate at 57.26%, 37.93%, and 23.02% respectively [1] - The closing prices and highest prices for the top three stocks are as follows: Huayin International Holdings at 1.370 and 1.950, Dingyifeng Holdings at 0.770 and 0.800, and Youquhui Holdings at 3.550 and 3.580 [1] - Other notable stocks that reached their 52-week highs include China Antibody-B (03681) with a high rate of 21.62% and Fengcheng Holdings (02295) at 19.52% [1] Group 2 - The report also lists stocks that reached their 52-week lows, with Des Holdings (08437) showing the largest decline at -38.79%, followed by Dimi Life Holdings (01667) at -20.50% [3] - The closing prices and lowest prices for the top three stocks that reached their lows are: Des Holdings at 0.177 and 0.071, Dimi Life Holdings at 0.140 and 0.128, and Lujizhi Technology (01745) at 0.197 and 0.194 [3] - Other stocks with significant declines include GBA Group (00261) at -11.48% and Baide International (02668) at -10.88% [3]

Financial Performance - For the six months ended December 31, 2024, Sinopharm Tech Holdings Limited reported revenue of HKD 18,898,000, a slight increase from HKD 18,844,000 in the same period of 2023, representing a growth of 0.29%[5] - The gross profit for the same period was HKD 6,500,000, significantly up from HKD 3,121,000 in 2023, indicating a gross margin improvement of approximately 108.8%[5] - Operating loss increased to HKD 1,075,000 from HKD 350,000 year-over-year, reflecting a deterioration in operational efficiency[5] - The net loss attributable to shareholders for the period was HKD 5,513,000, compared to HKD 2,876,000 in 2023, representing an increase in loss of 91.0%[5] - Total comprehensive loss for the period was HKD 4,367,000, worsening from HKD 3,315,000 in the same period last year[7] - The basic loss per share for the period was HKD 0.0217, compared to HKD 0.0157 in the prior year, indicating a worsening loss per share situation[7] - The company reported a total revenue of HKD 18,844,000 from supply chain services for the six months ended December 31, 2023, with a slight increase from HKD 18,898,000 in the same period of 2024[22][28] - The group recorded unaudited consolidated revenue of HKD 18,900,000 for the year 2024, a 1% increase from HKD 18,800,000 in 2023[64] - Gross profit margin increased to approximately 34% in 2024, compared to 17% in 2023[64] - The group reported a loss attributable to shareholders of HKD 5,500,000 in 2024, compared to a loss of HKD 2,900,000 in 2023[64] Financial Position - Current liabilities amounted to HKD 63,193,000, a decrease from HKD 249,436,000 as of June 30, 2024, indicating improved liquidity management[9] - The company's total assets less current liabilities showed a net negative position of HKD 18,511,000, compared to HKD 204,946,000 previously, indicating a substantial decline in financial health[9] - Cash and cash equivalents increased to HKD 3,347,000 at the end of the reporting period, compared to HKD 8,505,000 at the end of the previous year, reflecting a decrease of 60.7%[17] - Total assets as of December 31, 2024, amounted to HKD 44,682,000, an increase from HKD 44,490,000 as of June 30, 2024[24] - The company's total liabilities increased to HKD 63,341,000 as of December 31, 2024, compared to HKD 250,089,000 as of June 30, 2024[24] - The debt-to-asset ratio improved to 12% as of December 31, 2024, down from 162% on June 30, 2024[74] Cash Flow - The company reported net cash used in operating activities of HKD (781,000) for the six months ended December 31, 2024, an improvement from HKD (1,317,000) in the same period of 2023[17] - The company reported a net cash inflow from financing activities of HKD 1,488,000, a decrease from HKD 8,271,000 in the previous year, indicating reduced financing activity[17] - The company’s operating cash flow showed a slight improvement, with cash used in operations decreasing from HKD (1,331,000) to HKD (784,000) year-over-year[17] Financing Costs - The financing costs rose to HKD 3,383,000 compared to HKD 1,889,000 in the previous year, marking an increase of 79.0%[5] - The company incurred financing costs of HKD (3,383,000) during the reporting period, contributing to the overall loss[21] - The company recorded financing costs of HKD 3,383,000 for the six months ended December 31, 2024, up from HKD 1,889,000 in the same period of 2023[31] Equity and Share Capital - The company's total equity attributable to shareholders decreased to HKD (13,919,000) as of December 31, 2024, from HKD (176,324,000) as of December 31, 2023, indicating a significant reduction in equity[14] - The company completed a capital reorganization, reducing the par value of each issued share from HKD 0.3125 to HKD 0.0125, effective November 6, 2024[81] - The company's authorized share capital remains at HKD 200,000,000, divided into 12,800,000,000 ordinary shares and 3,200,000,000 non-voting convertible preferred shares[53] Debt Management - The company issued convertible bonds with a principal amount of HKD 50,000,000 at a coupon rate of 7%[44] - The company completed a debt capitalization agreement, issuing 547,609,590 convertible preferred shares at HKD 0.1 each to offset the total debt amount[48] - The total debt reduction from the loan capitalizations is estimated to be approximately HKD 193,000,000, which will improve the company's capital structure and reduce interest burdens[109] - Following the completion of the Creative Big loan capitalization agreement, the total debt owed to Creative Big has been fully repaid, relieving the company of its obligations under this debt[119] Operational Strategy - The company plans to continue expanding its supply chain services and explore new markets as part of its growth strategy[26] - The group is focusing on expanding its supply chain services and health product distribution, aiming to enhance revenue sources and market opportunities[72] - The company aims to focus more on its business operations and seize future fundraising opportunities following the debt reduction[117] Management and Governance - The board of directors consists of executive directors Mr. Ho Kam Kin and Ms. Kwok Suk Yi; non-executive director Mr. Cheng Yan Kit; and independent non-executive directors Mr. Lau Fei, Mr. Hsu Tung An, and Mr. Cheung Pik Lun[129] - The company has complied with the GEM Listing Rules and has established an audit committee consisting of three independent non-executive directors[127] - The company has adopted the trading code of conduct as per GEM Listing Rules for directors' securities transactions, confirming compliance throughout the review period[126] Employee and Management Compensation - Short-term benefits for directors and key management personnel amounted to HKD 1,120,000 for the six months ended December 31, 2024, compared to HKD 1,367,000 for the same period in 2023[61] - The company employed 30 staff members as of December 31, 2024, down from 33 on June 30, 2024[88] Shareholder Information - As of December 31, 2024, Integrated Asset holds 321,694,520 shares, representing approximately 50.77% of the company's total shares[97] - Quantum Worldwide Investment Limited owns 150,000,000 shares, accounting for about 23.67% of the company's total shares[97] - The board of directors and key executives hold a total of 2,999,600 ordinary shares, representing approximately 0.48% of the company's issued share capital[91] Compliance and Regulatory Matters - The company has not adopted any new accounting standards that would have a significant impact on its financial reporting for the current period[19] - The company has not engaged in any arrangements that would allow directors or key executives to benefit from purchasing shares or bonds during the reporting period[95] - The company has no knowledge of any significant matters affecting the group from the end of the reporting period to the report date[62]

Financial Performance - For the six months ended December 31, 2024, the company reported revenue of HKD 18,898,000, a slight increase from HKD 18,844,000 in the same period of 2023, representing a growth of 0.29%[6] - Gross profit for the same period was HKD 6,500,000, significantly up from HKD 3,121,000, indicating a year-over-year increase of 108.83%[6] - The company incurred a loss before tax of HKD 4,458,000, compared to a loss of HKD 2,239,000 in the previous year, reflecting an increase in losses of 99.57%[6] - The basic loss per share for the period was HKD 2.17, compared to HKD 1.57 in the prior year, indicating a deterioration in earnings per share[8] - The company's total comprehensive loss for the period was HKD 4,367,000, compared to a loss of HKD 3,315,000 in the previous year, representing an increase of 31.69%[8] - For the six months ended December 31, 2024, the company reported a loss attributable to shareholders of HKD 5,513,000, compared to a loss of HKD 2,876,000 for the same period in 2023, representing an increase in loss of approximately 92%[15] - The company recorded a pre-tax loss of HKD 5,513,000 for the six months ended December 31, 2024, compared to a pre-tax loss of HKD 2,876,000 for the same period in 2023, indicating a deterioration in financial performance[38] - The group reported a loss attributable to shareholders of HKD 5,500,000 in 2024, compared to a loss of HKD 2,900,000 in 2023[65] Assets and Liabilities - Total assets as of December 31, 2024, were HKD 39,004,000, compared to HKD 38,068,000 as of June 30, 2024, showing a slight increase of 2.45%[10] - Total assets as of December 31, 2024, amounted to HKD 44,682,000, an increase from HKD 44,490,000 as of June 30, 2024, reflecting a growth of 0.43%[25] - Current liabilities totaled HKD 63,193,000, a decrease from HKD 249,436,000, indicating a reduction of 74.69%[10] - Total liabilities increased to HKD 63,341,000 as of December 31, 2024, up from HKD 50,089,000 as of June 30, 2024, representing a rise of 26.4%[25] - The company’s total liabilities to total assets ratio increased to 1.42 as of December 31, 2024, compared to 1.12 as of June 30, 2024, indicating a higher financial leverage[25] - The debt-to-asset ratio improved to 12% as of December 31, 2024, down from 162% on June 30, 2024[75] Cash Flow and Financing - Cash and cash equivalents increased to HKD 3,347,000 at the end of the reporting period, compared to HKD 8,505,000 at the end of the previous year, reflecting a decrease of approximately 60%[18] - The company generated a net cash outflow from operating activities of HKD 781,000 for the six months ended December 31, 2024, compared to HKD 1,317,000 for the same period in 2023, showing a reduction in cash burn[18] - The company incurred financing costs of HKD 3,383,000 during the reporting period, contributing to the overall loss[22] - The company reported a significant increase in financing costs to HKD 3,383,000 from HKD 1,889,000, which is an increase of 79.00%[6] - The company issued convertible preferred shares amounting to HKD 148,015,000 as part of its financing activities during the period[15] - The company issued convertible bonds amounting to HKD 50,000,000 with a coupon rate of 7%[45] Inventory and Receivables - The company's inventory increased significantly to HKD 16,546,000 from HKD 3,537,000, marking a rise of 368.73%[10] - Trade receivables amounted to HKD 15,262,000 as of December 31, 2024, down from HKD 22,442,000 as of June 30, 2024, representing a decrease of 32%[41] - Other receivables and prepayments were HKD 6,257,000 as of December 31, 2024, compared to HKD 11,859,000 as of June 30, 2024, indicating a decline of 47%[41] - Total receivables, net of provisions for bad debts, stood at HKD 19,111,000 as of December 31, 2024, down from HKD 31,891,000 as of June 30, 2024, a decrease of 40%[41] Capital Structure and Shareholder Information - The company’s total equity attributable to shareholders decreased to HKD (13,919,000) as of December 31, 2024, from HKD (172,733,000) as of December 31, 2023, indicating a significant improvement in equity position[15] - As of December 31, 2024, the total issued and paid-up capital was HKD 155,936,000, up from HKD 57,404,000 as of July 1, 2024, an increase of 171%[51] - The company has established a stock option plan as of June 9, 2021, for incentivizing employees[94] - Directors and key executives hold a total of 1,600,000 ordinary shares each, representing 0.25% of the company’s equity[92] - Integrated Asset holds 321,694,520 shares, representing approximately 50.77% of the company's total shares[98] - Quantum Worldwide Investment Limited owns 150,000,000 shares, accounting for about 23.67% of the company's total shares[98] Corporate Governance and Compliance - The company has adhered to the GEM Listing Rules and corporate governance codes, with no significant deviations reported during the review period[124] - The audit committee, consisting of three independent non-executive directors, has reviewed the unaudited results for the six months ending December 31, 2024, ensuring compliance with applicable accounting standards[128] - The board of directors consists of executive directors Mr. Ho Kam Kin and Ms. Kwok Suk Yi; non-executive director Mr. Cheng Yan Kit; and independent non-executive directors Mr. Liu Fei, Mr. Xu Dong An, and Mr. Cheung Pik Lun[130] Future Outlook and Strategic Focus - The group is focusing on expanding its supply chain services and health products, aiming to enhance its revenue sources and market opportunities[73] - The company currently has no major future investment or capital asset plans, but will continue to monitor industry conditions[88] - The company has no knowledge of any significant matters affecting the group since the end of the reporting period[63]

Financial Performance - For the six months ended December 31, 2023, the company reported revenue of HKD 18,844,000, an increase of 25.0% compared to HKD 15,025,000 for the same period in 2022[3] - The gross profit for the six months was HKD 3,121,000, reflecting a slight increase of 2.7% from HKD 3,039,000 in the previous year[3] - The company incurred a loss before tax of HKD 2,239,000 for the six months, compared to a profit of HKD 15,769,000 in the same period last year, indicating a significant decline[3] - The net loss attributable to equity holders for the six months was HKD 2,876,000, compared to a profit of HKD 15,408,000 in the prior year[3] - The company reported a basic loss per share of HKD 0.29 for the three months ended December 31, 2023, compared to earnings of HKD 6.07 per share in the same period last year[5] - The company reported a net loss of HKD 2,876,000 for the six months ended December 31, 2023, compared to a profit of HKD 15,408,000 in the same period last year, representing a significant decline[9] - The company’s total comprehensive income for the period was a loss of HKD 4,151,000, compared to a gain of HKD 13,692,000 in the same period last year[9] - The company reported a loss attributable to equity holders of HKD 2,900,000, compared to a profit of HKD 15,400,000 in the previous year[50] Assets and Liabilities - Total assets as of December 31, 2023, amounted to HKD 36,702,000, up from HKD 27,045,000 as of June 30, 2023[6] - The company's current liabilities increased to HKD 228,739,000 from HKD 213,236,000, indicating a rise in financial obligations[6] - The net liabilities of the company stood at HKD 182,509,000 as of December 31, 2023, compared to HKD 179,754,000 at the end of June 2023[8] - The total liabilities as of December 31, 2023, were HKD 228,739,000, with classified liabilities of HKD 46,296,000[17] Cash Flow and Liquidity - The company’s cash and bank balances increased to HKD 8,505,000 from HKD 1,776,000, indicating improved liquidity[6] - Total cash and cash equivalents increased to HKD 8,505,000 as of December 31, 2023, up from HKD 7,283,000 at the end of the previous year, indicating a growth of approximately 16.7%[11] - Operating cash flow for the period was a net outflow of HKD 1,317,000, a decrease from a net inflow of HKD 4,720,000 in the prior year, reflecting a change of approximately 128%[11] - The company’s cash flow from financing activities generated a net inflow of HKD 8,271,000, compared to an outflow of HKD 290,000 in the previous year[11] Revenue Segments - Revenue from the manufacturing and distribution segment amounted to HKD 18,844,000, with a segment loss of HKD 2,046,000 for the period[15] - For the six months ended December 31, 2023, the total revenue from the "Internet+" services (supply chain) was HKD 18,844,000, an increase of 74.2% compared to HKD 10,825,000 in the same period of 2022[21] - The revenue from manufacturing and distribution of personal protective equipment was HKD 4,200,000, contributing to a total revenue of HKD 18,844,000 for the period[21] - The "Internet+" service segment generated revenue of HKD 18,800,000, a 74% increase compared to the previous year[51] Financing and Capital Structure - The company incurred financing costs of HKD 1,889,000 during the reporting period, contributing to the overall loss[15] - The company has convertible bonds with a principal amount of HKD 89,625,000, with a conversion price adjusted to HKD 0.598 per share after a share split[40] - The company issued convertible bonds with a principal amount of HKD 50,000,000, maturing on February 20, 2023, with an annual interest rate of 7%[45] - The adjusted conversion price for the convertible bonds is HKD 0.221 per share, allowing for the conversion into a maximum of 405,542,986 shares[44] - As of December 31, 2023, the total outstanding balance of the convertible bonds was HKD 105,747,000, which includes the principal and accrued interest[44] - The company has a total issued and paid-up capital of HKD 57,404,000 as of December 31, 2023[47] - The company has not issued any dividends, maintaining an expected dividend yield of 0%[46] Corporate Governance - The company has adopted and complied with the corporate governance code as per GEM listing rules, with some deviations noted[96] - The roles of Chairman and CEO are held by the same executive director, which the board believes benefits the company's business outlook[97] - The company confirmed compliance with the trading code of conduct for directors throughout the review period[98] - The company had only one independent non-executive director after the resignation of Dr. Liu Da Bei on August 3, 2023, which is below the minimum requirement of three as per GEM Listing Rule 5.05(1)[99] - The company appointed Mr. Xu Dong'an as an independent non-executive director on August 15, 2023, to comply with GEM Listing Rule 5.05A[99] - The company appointed another independent non-executive director, Mr. Xiang Bilun, on September 15, 2023, to meet the minimum requirement of three independent non-executive directors[99] - The Audit Committee consists of three independent non-executive directors, including Mr. Liu Fei as the chairman, Mr. Xu Dong'an, and Mr. Xiang Bilun[101] Staff and Employment - As of December 31, 2023, the company employed 18 staff members in Hong Kong and China, down from 19 as of June 30, 2023[70] Legal and Regulatory Matters - The company is currently negotiating with Creative Big Limited regarding a winding-up petition involving a claim of HKD 53,106,849 for the repayment of convertible bonds[49] - The hearing for the winding-up petition has been postponed to April 3, 2024, with no winding-up order issued as of the report date[72] - The company is seeking professional advice to assess the potential impact of the petition on its operations and financial condition[73] - There are no other pending winding-up petitions against the company as of the report date[73]